Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura

Blood

Volumn 115, Issue 1, 2010, Pages 29-31

  Arnold, Donald M ^a,b   Nazi, Ishac ^a   Santos, Aurelio ^a   Chan, Howard ^a   Heddle, Nancy M ^a   Warkentin, Theodore E ^a   Kelton, John G ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GUM HYPERTROPHY; HUMAN; HYPERTROPHY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; LEUKOPENIA; MALE; PRIORITY JOURNAL; REFRACTORY THROMBOCYTOPENIA; REVERSIBLE TREMOR; SPLENECTOMY; THROMBOCYTE COUNT; TREMOR; CHRONIC DISEASE; CLINICAL TRIAL; DRUG COMBINATION; MIDDLE AGED; RECURRENT DISEASE;

AZATHIOPRINE; CHRONIC DISEASE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENCE;

EID: 74949115473     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-06-222448     Document Type: Article

References (18)

1. McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood. 2004;104(4):956-960.
2. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97(9):2549-2554.
3. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9664): 641-648.
4. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395-403.
5. Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med. 2004;140(2):112-120.
6. Figueroa M, Gehlsen J, Hammond D, et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med. 1993; 328(17):1226-1229.
7. Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood. 2007; 110(10):3526-3531.
8. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003; 120(4):574-596.
9. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children: Report from an International Working Group. Blood. 2009; 113(11):2386-2393.
10. George JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost. 2006;4(8):1664-1672.
11. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant. 1996;10(1 pt 2): 77-84.
12. Liu JO. Calmodulin-dependent phosphatase, kinases, and transcriptional corepressors involved in T-cell activation. Immunol Rev. 2009;228(1): 184-198.
13. Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol. 2006;81(1):19-25.
14. Hou M, Peng J, Shi Y, et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;70(6):353-357.
15. Choudhary DR, Naithani R, Mahapatra M, Kumar R, Mishra P, Saxena R. Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura. Haematologica. 2008; 93(10):e61-e62.
16. Emilia G, Luppi M, Morselli M, Forghieri F, Potenza L, Torelli G. A possible role for low-dose cyclosporine in refractory immune thrombocytopenic purpura. Haematologica. 2008;93(7):1113-1115.
17. McMillan R. Long-term outcomes after treatment for refractory immune thrombocytopenic purpura. N Engl J Med. 2001;344(18):1402-1403.
18. Heddle NM, Cook RJ, Webert KE, Sigouin C, Rebulla P. Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion. 2003;43(6):742-752.